Physician profile

Patrick A Polach

Family Medicine · Turlock, CA

NPI 1861812984

$209.95

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$16.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $44.05 2019
Boehringer Ingelheim Pharmaceuticals, INC. $25.56 2019
Horizon Therapeutics Plc $22.58 2019
Merck Sharp & Dohme LLC $22.17 2019
Exact Sciences Corporation $16.46 2024 Cologuard Collection Kit
Allergan, INC. $16.19 2019
Pfizer INC. $13.25 2019
Silk Road Medical, INC. $13.08 2019
Novo Nordisk INC $12.71 2019
Glaxosmithkline, LLC. $12.10 2019
Lilly USA, LLC $11.80 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Patrick A Polach

$209.95

in general payments reported 2019-2025

Years
2019-2024
Top company
Amgen INC.

https://glasscript.com/doctor/4215759/patrick-a-polach

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.